Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Approval Or Launch Will Trigger Notification To Market

Executive Summary

Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.

You may also be interested in...



Coherus Reveals US Launch Plans For Interchangeable Ranibizumab

Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.

Fresenius Delivers First US Biosimilar Approval

Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.

The Generics Bulletin Top 50, Part Three: Newcomers Climb Into Bottom Table

In the third section of this year’s Generics Bulletin Top 50, a handful of new entrants make their way into the bottom of the rankings, while some volatility is seen among longstanding ranking companies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel